BioSpace News Archive

Biotech Beach

Inhibrx Announces Presentations at SITC 2021

Inhibrx, Inc. announced today that the Company will be presenting three poster presentations at the Society for Immunotherapy of Cancer’s (SITC) annual meeting, to be held in Washington, D.C.

November 3, 2021
·
2 min read
Pharm Country

Insmed To Participate in Three November Conferences

Insmed Incorporated Inc. today announced that management will participate in the virtual investor conferences.

November 3, 2021
·
1 min read
Lone Star Bio

Data from ImmunoGenesis’ Lead Programs to be Presented at Society for Immunotherapy of Cancer (SITC) Conference

ImmunoGenesis today announced the acceptance of six poster presentations on its lead development programs at the Society for Immunotherapy of Cancer 36 th Annual Meeting (SITC 2021), which will be held November 10-14, 2021 , in Washington, DC

November 3, 2021
·
3 min read
Pharm Country

Geistlich Pharma Launches Geistlich Nexo-Gide® Dual Surface Membrane for Tendon Management and Protection

The Geistlich Surgery, USA business unit of Geistlich Pharma AG, a family owned, Swiss-based global leader in regenerative solutions, is proud to announce the launch of its latest advancement: Geistlich Nexo-Gide® Dual Surface Membrane.

November 3, 2021
·
2 min read
Genetown

Minerva Neurosciences Announces FDA Recommendation for Type C Meeting to Discuss Evidence for Use of Roluperidone as Monotherapy for the Treatment of Negative Symptoms in Patients with Schizophrenia in Advance of Potential NDA Submission

Minerva Neurosciences, Inc. today announced that the U. S. Food and Drug Administration (FDA) has denied the company’s request for a pre-NDA meeting for roluperidone and responded that a Type C guidance meeting would be more appropriate to discuss the evidence for use of roluperidone as monotherapy.

November 3, 2021
·
3 min read
Biotech Beach

Autobahn Therapeutics Announces New Preclinical Data Supporting its Novel Brain-Targeting Platform for the Development of Therapeutics for CNS Disorders

Autobahn Therapeutics today announced new preclinical data highlighting the company’s thyroid hormone-targeted approach to precisely deliver tailored therapeutics to the brain for the treatment of a range of CNS disorders.

November 3, 2021
·
4 min read
Biotech Bay

The Parker Institute for Cancer Immunotherapy and the Cancer Research Institute Announce First Patients Dosed in First-Line Pancreatic Cancer Platform Trial

The Parker Institute for Cancer Immunotherapy and the Cancer Research Institute announced the dosing of the first patients in the REVOLUTION trial, a phase I, open label platform study of novel immunotherapy combinations for first-line treatment of metastatic pancreatic cancer.

November 3, 2021
·
6 min read
ENYO Pharma Announces Two Vonafexor Data Presentations at AASLD The Liver Meeting

ENYO Pharma today announced that two abstracts on Vonafexor were accepted one as oral presentation and one as poster during the upcoming The Liver Meeting® 2021, organized by the American Association for the Study of Liver Diseases (AASLD) on November 12-15, 2021.

November 3, 2021
·
4 min read
Business

Novan to Report Third Quarter 2021 Financial Results on November 10, 2021Company to host conference call and webcast on Wednesday, November 10, 2021, at 8:30 a.m. ET

Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its third quarter 2021 financial results on Wednesday, November 10th.

November 3, 2021
·
1 min read
Riverside University Health System Medical Center, Skymount Medical Begin U.S. Clinical Trial for COVID-19 Oral Therapeutics Discovered Using Artificial Intelligence

Skymount Medical has partnered with Riverside University Health System (RUHS) Medical Center to conduct the first U.S. clinical trial on the efficacy of COVID-19 oral therapeutics discovered by LSU researchers using artificial intelligence (AI).

November 3, 2021
·
4 min read